The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Alexey Danilov, MD, PhD, discusses unmet needs in hematologic malignancies to be discussed at the Bridging the Gaps in Hematologic Malignancies meeting.
Real-world ruxolitinib use in chronic GVHD was primarily in the second- or third-line, lasted for a median of 8 months, and involved dose adjustments.
Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.
Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.
In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.
Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.
Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.
Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.
Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.
Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.
Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.
Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.
Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.
Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.